Member access

4-Traders Homepage  >  Shares  >  Euronext Paris  >  SANOFI    SAN   FR0000120578

SANOFI (SAN)

2420
Delayed Quote. Delayed Euronext Paris - 08/22 11:39:43 am
79.43 EUR   -1.44%
9h ago SANOFI : Zealand Pharma announces Interim report for H1 2014
12h ago GENZYME : Assigned Patent
1d agoDJEUROPE MARKETS : Raiffeisen Rallies, Miners Slip: Europe Movers
SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 

Sanofi: Tests Show Zaltrap Improves Colorectal Cancer Survival Rate

10/08/2012 | 01:44am US/Eastern
Recommend:
0

French drug company Sanofi SA (>> SANOFI) Monday said results from the pivotal Phase III Velour study evaluating Zaltrap showed improvement in overall survival rate to colorectal cancer.

MAIN FACTS:

- Sanofi said the Journal of Clinical Oncology published the results of the study evaluating Zaltrap effects.

- In the Velour trial evaluating metastatic colorectal cancer patients previously treated with an oxaliplatin-containing regimen, Zaltrap in combination with the Folfiri chemotherapy regimen (5-fluorouracil, leucovorin, irinotecan) showed a statistically significant improvement in overall survival, progression-free survival, and the overall tumor response rate versus placebo plus Folfiri.

- The Velour data supported the regulatory approval of Zaltrap by the U.S. Food and Drug Administration (FDA) on August 3, 2012 after a Priority Review.

- Zaltrap is under review at the European Medicines Agency and other regulatory agencies worldwide, Sanofi says.

-Write to Inti Landauro at inti.landauro@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : SANOFI
Recommend :
0
React to this article
Latest news on SANOFI
9h ago SANOFI : Zealand Pharma announces Interim report for H1 2014
12h ago GENZYME : Assigned Patent
1d agoDJEUROPE MARKETS : Raiffeisen Rallies, Miners Slip: Europe Movers
1d ago GENZYME : FDA Approves U-M Invented Drug for Gaucher Disease
1d ago Illumina Announces Strategic Partnerships with AstraZeneca, Janssen and Sanof..
1d agoDJEUROPE MARKETS : Raiffeisen Rallies, Miners Slip: Europe Movers
1d ago Veracyte Reports Second Quarter Results
1d ago SANOFI : Positive Data for Fluzone Published in The New England Journal of Medic..
1d ago Veracyte Reports 2Q 2014 Financial Results
2d ago SANOFI : Patent Issued for Monoclonal Antibodies and Uses
Advertisement
Chart
Duration : Period :
SANOFI Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Income Statement Evolution
SANOFI : Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF